

The Most Human Way to Heal.



www.biotissue.com

Regenerate. Restore. Recover.

The BioTissue Surgical comprehensive family of human amniotic membrane allografts helps deliver the natural healing properties of human birth tissue to wound and surgical environments.¹

When it comes to your patients, good enough is never enough.

We are in a race against time to heal wounds. Healing wounds faster and with fewer applications is the BioTissue difference.

BioTissue Where Science Meets Nature

The First to Recognize the Natural Healing Potential of the HC-HA/PTX3 Complex

CryoTek® Cryopreservation

The BioTissue proprietary CryoTek cryopreservation process is the tissue processing method shown to produce an allograft comparable to the native tissue.^{2,3} In conventional heat dehydration processing, critical biological components naturally found in birth tissue including HC-HA/PTX3 —are degraded, which may limit the tissue's healing properties.²

CryoTek technology utilizes controlled deep freezing to effectively preserve the functional and structural integrity of the birth tissue.^{2,3}

CryoTek minimizes the risk of an immune reaction and preserves the functional components of the extracellular matrix.

For over 36 years, our pioneering scientists have focused on understanding the regenerative features of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in human birth tissue regenerative healing.

BioTissue Surgical allografts are aseptically processed, devascularized and cell devitalized.

SteriTek® Preservation

Our proprietary SteriTek preservation process, utilized with Neox RT, yields a shelf-stable product without heat dehydration of the tissue. The tissue is cleaned, processed and packaged in a manner similar to our CryoTek cryopreservation process, but utilizes saline as its storage medium. It is then terminally sterilized using gamma irradiation, yielding a fully hydrated product that can be stored at a controlled room temperature.

Biological Tissue Provides the Most Human Form of Healing

Neox°

Neox[®] 1K

Neox 1K is a cryopreserved, ultra-thick human amniotic
membrane derived from umbilical cord used as an adjunct
treatment for chronic and acute, partial- and
full-thickness wounds.⁴⁻¹⁰The market-first cryopreserved, ultra-thick human amniotic
membrane allograft derived from umbilical cord used as an
adjunct for surgical applications. Recent studies suggest
that Clarix 1K helps expedite and improve surgical wound
healing, reducing overall time for skin healing by 30% in
patients undergoing total ankle arthroplasty.¹²

Studies suggest that these amniotic membrane allografts
help promote healing in complex diabetic foot ulcers
complicated with osteomyelitis, comparing favorably to
the Standard of Care.^{5,7,8} It's up to 10x thicker than amniotic
membrane alone,^{2,3} which may increase longevity in the
wound bed, potentially reducing the number applications
needed and the cost of care.¹¹patients undergoing total ankle arthroplasty.¹²Data and the cost of care.¹¹Clarix 1K is up to 10x thicker than allografts containing
amniotic membrane alone,^{2,3} which may increase longevity
in the surgical site.

Neox RT

Neox RT is a sterile, ultra-thick human amniotic membrane allograft derived from umbilical cord for applications such as chronic and acute partial and full-thickness wounds. Neox RT delivers the benefits of a human amniotic allograft in a shelf-stable product with room temperature storage.

Neox RT is manufactured, using the SteriTek preservation process, stored in saline (0.9% NaCl) and terminally sterilized via gamma irradiation, yielding a shelf-stable product.

Neox 100

Neox 100 is a cryopreserved, human amniotic membrane allograft. Neox 100 is a thinner allograft alternative to Neox 1K making it ideal for superficial wound areas.

The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.



36 Years

680,000+

of National Institute of Health (NIH) funded research transplantations performed



Clarix[®] 1K

This ultra-thick allograft is easier to handle and requires less preparation time compared to other frozen cryopreserved amniotic allografts.

Clarix 100

Clarix 100 is a cryopreserved, human amniotic membrane allograft. Clarix 100's thinner design is ideal for surgical applications that favor a minimal approach/incision or where space is anatomically compromised. The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.



380+ peer-reviewed publications studying our technology

[<u>=☆</u> =]

40+ issued patents

The BioTissue Difference

The BioTissue comprehensive family of allografts provides mother nature's most natural gift of healing. Our family of allografts supports expedited regenerative healing across a wide range of specialties as an adjunct for acute and chronic wound applications by helping to:

Manage discomfort and adhesions

Facilitate wound healing

Expedite functional recovery while reducing the cost of care^{5,9,10,13}

The time is now to achieve a new Standard of Care.

Together we can make a difference in surgical and chronic wound healing.

We will continue to move forward with an open mind, knowing that everything is possible.

Scheffer Tseng, MD, PhD, Co-Founder and Chief Technology Officer

References

- 1. Tseng SC. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFh1-ORSFh8.
- 2. Cooke M, Tan EK, Mandrycky C, He H, O'Connell J, Tseng SC. J Wound Care. 2014;23(10):465-476.3.
- 3. Tan EK, Cooke M, Mandrycky C, et al. J Biomaterial T Eng. 2014;4:379-388.
- 4. Tsena SC. Invest Ophthalmol Vis Sci. 2016:57(5):ORSFh1-ORSFh8.
- 5. Caputo WJ, Vaguero C, Monterosa A, et al. Wound Repair Regen. 2016;24(5):885-893.
- 6. Couture M. Wounds, 2016:28(7):217-25.
- 7. Maraolis DJ, Allen-Taulor L, Hoffstad O, Berlin JA, Diabetes Care 2002; 25: 1835–9.
- 8. Fife CE, Eckert KA, Carter MJ. Adv Wound Care 2018; 7: 77–94.
- 9. Raphael A. J Wound Care, 2016;25(Sup7);S10-17.
- 10. Raphael A. Gonzales J. J Wound Care, 2017;26(Sup10):S38-44.
- 11. Voigt, J, et al. PDB51 Cost Analysis Comparing Two Human Allografts In Healing Diabetic Foot Ulcers Over A 16 Week Period. Abstract Only. Volume 22, Supplement 2, S148-S149, May 01, 2019 12. Bemenderfer TB, Anderson RB, Odum SM, Davis WH. J Foot Ankle Surg.
- 13. Marston WA, Lantis II JC, Wu SC, et al. Wound Rep Reg. 2020;1-6.

7300 Corporate Drive, Suite 700, Miami, FL 33126 | 888.296.8858 © 2022 BioTissue, Inc. All rights reserved | US-AMX-2200000



Neox, CryoTek, SteriTek and BioTissue are registered trademarks of TissueTech, Inc. All other trademarks used herein are proprietary to their respective owners. Amniox Medical, Inc. is now doing business as BioTissue Surgical.

BioTissue Surgical products are authorized under the regulations of the U.S. Food and Drug Administration (FDA) governing the manufacture and distribution of Human Tissue Products. They are marketed as structural tissue products for homologous use and are used by physicians as barriers, wound coverings, conduits, and/or cushions in the treatment of their patients.